Abstract
Background and study aim: Inflammatory bowel disease (IBD) include a spectrum of immune-mediated chronic disorders. The aim of this study is to evaluate the efficacy of vitamin B6 supplementation on laboratory markers and clinical outcomes in patients with ulcerative colitis. Patients and methods: In this double-blind placebo-controlled randomized clinical trial ulcerative colitis patients were randomly divided into two groups, intervention (usual treatment plus vitamin B6 (40 mg / day)) and placebo group (usual treatment plus placebo). The serum levels of inflammatory markers measured and compared at the beginning and the end of intervention. Results: Overall forty patients were randomly selected to participate in this trial. Age range of participants was between 25-65 years and 3.43% of patients (13 cases) were males. Baseline characteristics of two groups were equal. The mean serum level of homocysteine after intervention in placebo and vitamin B6 groups were 9.05±3.45 and 16.31±20.52 respectively (P= 0.205). There were no significant differences between serum levels of homocysteine, CRP (P=0.328), ESR (P=0.329), calprotectin (P=0.683) and stool frequency after 6 months intervention in univariate analysis. In multivariate analysis stool frequency was significantly greater in vitamin B6 group in comparison with placebo group (P = 0.01). Conclusion: We couldn’t find any significant effect of vitamin B6 supplementation on duration and severity of ulcerative colitis and even stool frequency in vitamin B6 group increased.
Highlights
Inflammatory bowel disease (IBD) include a spectrum of immunemediated chronic disorders with two major types of ulcerative colitis (UC) and Crohn's disease (CD) [1]
Since vitamin B6 deficiency is prevalent among patients with ulcerative colitis and synthesis of H2S is dependent on enzymes that require vitamin B6 as a cofactor, and based on its role in tissue repair and suppression of inflammation in experimental studies, this study designed to evaluate efficacy of vitamin B6 supplementation on reduction of inflammatory markers, serum homocysteine level and clinical outcomes in ulcerative colitis patients
Data analysis in our study showed that there was no significant difference between intervention and control groups in terms of plasma homocysteine level, mean ESR, CRP, and calprotectin excretion before and after intervention (P> 0.05)
Summary
Inflammatory bowel disease (IBD) include a spectrum of immunemediated chronic disorders with two major types of ulcerative colitis (UC) and Crohn's disease (CD) [1]. Previous studies in experimental colitis have shown that HHcy exacerbate mucosal inflammation and administration of H2S can reduce severity of ulcers in mice [14]. Since vitamin B6 deficiency is prevalent among patients with ulcerative colitis and synthesis of H2S is dependent on enzymes that require vitamin B6 as a cofactor, and based on its role in tissue repair and suppression of inflammation in experimental studies, this study designed to evaluate efficacy of vitamin B6 supplementation on reduction of inflammatory markers, serum homocysteine level and clinical outcomes in ulcerative colitis patients. Inflammatory bowel disease (IBD) include a spectrum of immune-mediated chronic disorders. The aim of this study is to evaluate the efficacy of vitamin B6 supplementation on laboratory markers and clinical outcomes in patients with ulcerative colitis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
